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ABSTRACT 
 
Relapsed /refractory Hodgkin's lymphoma (HL) is treated with salvage chemotherapy and 
autologous stem-cell transplantation (ASCT). Optimal chemotherapy is unknown. We 
retrospectively analyzed outcomes of 58 patients treated with two cycles of high-dose ifosfamide 
and mitoxantrone (HDIM). HDIM consisted of ifosfamide 5 g/m
2
/day and MESNA  5 g/m2/day 
in continuous 24-hour infusion (days 1,2), MESNA 2.5 g/m
2
 over 12 hours (day 3), and 
mitoxantrone 20 mg/m
2
 (day 1) administered every two weeks. Stem cells were collected after the 
first cycle. Responding patients proceeded to ASCT. Toxicity was acceptable. Stem-cell 
mobilization was successful in 96% of patients. Overall response rate was 74% (89% in relapsing 
and 45% in refractory patients) with 31% complete remissions. After a median follow-up of 54 
months, 5-year event-free survival was 56% (69% for relapsing, 35% for refractory patients), and 
5-year overall survival was 67% (73% for relapsing, 55% for refractory patients). Significant 
adverse prognostic factors were refractoriness to previous therapy and HDIM failure. No 
differences in outcomes were noted between patients with early and late relapses nor between 
complete and partial responders. HDIM is a well tolerated and effective regimen for relapsed and 
refractory HL with excellent stem-cell mobilizing properties. Patients failing HDIM may still 
benefit from other salvage options. 
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INTRODUCTION 
 
Patients with relapsing or refractory Hodgkin's lymphoma (HL) are treated with salvage 
chemotherapy to induce remission and collect stem cells for autologous stem-cell transplantation 
(ASCT) [1, 2]. Responding patients are subsequently autografted. ASCT is not effective in 
chemoresistant patients. Therefore, inducing a response is of paramount importance. Different 
salvage chemotherapy regimens are usually used in this setting; miniBEAM (carmustine, 
etoposide, cytarabine, melfalan), DexaBEAM (dexamethasone + miniBEAM), DHAP 
(dexamethasone, cytarabine, cisplatin), ICE (ifosfamide, carboplatin, etoposide), GDP 
(gemcitabine, dexamethasone, cisplatin) and IGEV (ifosfamide, gemcitabine, etoposide, 
vinorelbine) [3-9]. Reported response rates and survival of these regimens are comparable. 
Patients who are refractory to front-line treatment (operationally defined as response lasting less 
than 3 months) have a significantly inferior prognosis. In some studies, patients relapsing less 
than 12 months from the end of front-line treatment (early relapses) fare worse than those 
relapsing later than 12 months since the end of treatment [6, 7].  
Salvage regimens consisting of high-dose ifosfamide and mitoxantrone were described in the 
nineties [10,11]. We performed a phase II trial of a similar regimen with an intensified dose of 
ifosfamide (HDIM) for stem-cell mobilization in patients with lymphoid malignancies and were 
favorably impressed by its antitumor activity [12]. HDIM has since been used as our standard 
salvage chemotherapy regimen in patients with relapsed or refractory HL eligible for ASCT. Here 
we report a retrospective analysis of our experience in 58 patients treated between 2003 and 2015. 
 
PATIENTS AND METHODS 
 
Patients 
 
Patients were eligible for inclusion in this analysis if they had relapsed or refractory HL, were at 
time of salvage treatment start eligible for ASCT and were scheduled to receive two cycles of 
HDIM. We identified 58 patients by retrospective chart review. Their characteristics are presented 
in Table 1. Twenty-one were refractory to prior treatment (duration of response to the last 
treatment less than 3 months), 19 were in early (duration of response to the last treatment 3-12 
months) and 18 in late relapse (duration of response to the last treatment more than 12 months). 
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None was known to be HIV positive. All patients were staged prior to treatment. Staging included 
careful palpation of peripheral nodes, CT scanning of the thorax, abdomen and pelvis and a bone 
marrow biopsy. PET was not used in all patients.  
 
TABLE 1 Patients' characteristics 
 
Age at relapse (years)  range  15-49  
median 30 
Gender (N)  M 34 
F 24 
HL type (N) NLP / NS / MC / 
NOS 
NS   /   MC 44   /   7 
NLP   /   NOS 2   /   5 
Front-line therapy (N) / 
 
ABVD   /   BEACOPP 48   /   1b+1e  
EBVP / COPP/ABV(D) / other 1   /   5   /   2 
Previous radiotherapy (N)   29                                             
Previous treatment lines (N)   range  1-3  
median 1 
Stage at relapse (N)  II  /  III 19   /   14  
IV  /  unknown 24   /   1 
Response to prior treatment (N)  refractory 21  
early relapse   /   late relapse 19   /   18 
 
 
N= number; NLP = nodular lymphocyte predominant; NS = nodular sclerosis; MC = mixed 
cellularity; NOS = not otherwise specified classical HL; ABVD = doxorubicin, bleomycin, 
vinblastine, dacarbazine; BEACOPP = bleomycin, etoposide, doxorubicin, cyclophosphamide, 
vincristine, procarbazine, prednisone; b = baseline; e = escalated; EBVP = epirubicin, bleomycin, 
vinblastin, prednisone; COPP/ABV(D) = hybrid or alternating COPP (cyclophosphamide, 
vincristine, procarbazine, prednisone) and ABVD 
 
 
Treatment 
 
HDIM consisted of ifosfamide 5 g/m
2
/day in continuous 24-hour infusion for 2 days, MESNA 5 
g/m
2
/day in continuous 24-hour infusion for 2 days and 2.5 g/m
2
 over 12 hours on day 3 and 
mitoxantrone 20 mg/m
2
 on day 1. G-CSF 10 ug/kg/day sc was started on day 6. At recovery, stem 
cells were collected by leukapheresis. A second cycle of HDIM was started on day 15 or after 
stem cell collection and hematologic recovery and was followed by G-CSF 5 ug/kg/day until 
leukocyte recovery. Patients with bone marrow infiltration were mobilized after the second HDIM 
cycle, provided the repeated bone marrow biopsy was negative. Treatment was given in an in-
patient setting. Patients were discharged after the end of chemotherapy and, if no complications 
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occurred, readmitted for stem cell collection, chemotherapy or ASCT. All received routine 
supportive care, including blood product transfusions and antiemetic prophylaxis with serotonin 
antagonists. 
Patients with chemosensitive disease were autografted after conditioning with BEAM. Areas not 
in complete remission (CR) prior to ASCT were irradiated with 30-36 Gy after recovery from 
transplantation. Twenty patients received posttransplant radiotherapy.  
 
Response assessment and follow-up 
 
Restaging by CT scanning was performed after two cycles of HDIM. Response was determined 
according to the older, pre-PET, version of standard criteria [13]. CT or PET-CT was repeated 
after ASCT (or posttransplant radiotherapy). Patients who achieved remission were followed 
clinically, every three months for the first 3 years, every 6 months during the 4
th
 and 5
th
 year and 
yearly thereafter. Imaging methods were repeated only if clinically indicated.  
Overall (OS) and event-free survival (EFS) were calculated from the date of HDIM start until the 
last follow-up, death or event, respectively. Events were defined as introduction of unplanned 
antitumor therapy due to lack of efficacy of HDIM, relapse, disease progression or death. 
 
Toxicity 
 
Toxicity was analyzed by chart review and graded using the National Cancer Institute Common 
Toxicity Criteria for Adverse Events v3.0. 
 
Data Analysis 
 
OS and EFS were estimated using the method of Kaplan & Meier. Fisher’s exact test was used for 
2x2 table analyses and log-rank test for survival comparisons. The assumed level of significance 
was 0.05.  
 
Ethics 
 
This is a non-interventional retrospective study of patient data performed with the approval of the 
Ethical Committee of the Medical School, University of Zagreb in accordance with pertinent 
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Croatian, EU and international rules and regulations and the Declaration of Helsinki. Prior to 
treatment all patients gave informed consent for intensive chemotherapy and autologous stem cell 
transplantation.   
 
RESULTS 
 
Toxicity 
 
There was no treatment-related mortality. The 2
nd
 cycle was not administered in 2 patients, one 
due to progressive disease and the other due to toxicity. Median time to the start of 2
nd
 cycle was 
16 days. As expected, hematological toxicity was universal. All patients developed severe 
granulocytopenia, 26% needed platelet or red blood cell transfusions; 73% had fever or proven 
infections (Table 2). Three patients had neurological side-effects: one delirium, one seizures and 
one syncope. One patient developed acute renal failure and received miniBEAM as the 2
nd
 cycle 
of therapy. Fourteen patients had nausea or vomiting, mostly while not receiving maximal 
prophylactic treatment; two had mucositis, three troublesome hiccups, one deep venous 
thrombosis and one an algic syndrome. Thirty did not have any significant non-hematological and 
non–infectious side-effects. All patients successfully recovered and none had to abstain from 
ASCT due to toxicity. 
 
TABLE 2 Severe side-effects of HDIM  
 
Side-effect No. of patients 
Grade 4 
Granulocytopenia 58 
Anemia 14 
Trombocytopenia 8 
 Grade 3 Grade 4 
Infections 38 3 
Nausea & vomiting 1 0 
Mucositis  2 0 
Delirium 1 0 
Syncope 1 0 
Acute renal failure 1 0 
Deep venous thrombosis 1 0 
 
As can be ascertained by routine clinical follow-up, no unusual symptomatic long-term toxicity 
was noted in survivors. A single patient developed secondary cancer (melanoma), and none had 
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clinically manifest cardiac failure. 
 
Stem-cell collection 
 
In two patients, stem cell collection was not performed due to HL progression. Stem-cell 
collection was successful (> 2x10
6
 CD34+ cells per kg body weight collected) in 54 patients 
(96%). The remaining two failed to mobilize after HDIM, but responded to plerixafor and were 
successfully autografted.  
Hematologic recovery after ASCT was not delayed in comparison to patients that had been treated 
with miniBEAM or DHAP at our center. 
 
Response to treatment and prognosis 
 
After two cycles of HDIM, 18 patients achieved CR, 24 partial remission (PR), 11 had stable 
disease (SD) and 4 progressive disease (PD), for a response rate of 74%. Data from restaging 
were not available for one patient. The response rate in primary refractory disease was 
significantly lower than in early and late relapse (45% vs. 89% vs. 89% respectively, p<0.001).  
In non-responders, different treatment regimens were tried (e.g. miniBEAM) in order to obtain a 
response and continue with auto- or allografting. Patients relapsing after ASCT were treated with 
DHAP, escalated BEACOPP or gemcitabine + steroids. A single patient received brentuximab-
vedotin; 9 underwent allo-SCT. 
After a median follow-up of survivors of 54 months (range 2-120 months), 16 patients (28%) 
have died and 26 (45%) had an event. Actuarial 5-year EFS of the whole group was 56%±7% 
(95% confidence interval) and OS 67%±7%. EFS was significantly worse in refractory in 
comparison to early or late relapsing patients, (5-year EFS 35%±10% vs. 67%±11%, vs. 
71%±11%, respectively; p=0.012) (Fig. 1). The difference in OS was not statistically significant 
(5-year OS 55%±11% vs. 74%±12% vs. 72%±12%, respectively; p=0.131) (Fig. 1). EFS and OS 
in early and late relapsing patients were similar. Beyond 5 years of follow-up a single patient 
relapsed, none died.  
 
 9 
 
FIG 1 Event-free survival (EFS) and overall survival (OS) of patients with late relapses (LR), 
early relapses (ER) and refractory (R) Hodgkin's lymphoma treated with HDIM 
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We analyzed the impact of additional possible prognostic factors on EFS and OS. Gender, HL 
type, front-line regimen, previous radiotherapy, B symptoms, stage and anemia did not influence 
outcomes. Response to HDIM was very important (Fig. 2). Patients achieving CR had a 5-year 
EFS of 78%±10%, PR 68%±10%, SD 18%±12 and PD 0% (CR and PR vs. SD and PD, p<0.001). 
Median EFS was not reached in responding patients and was 6 and 2 months in the latter two 
groups, respectively. Patients achieving CR had a 5-year OS of 76%±11%, PR 81%±9%, SD 
49%±17% and PD 25%±22% (CR and PR vs. SD and PD, p=0.044). Median OS was not reached 
in responding patients and was 39 and 2 months in the latter two groups, respectively.  
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FIG 2 Event-free survival (EFS) and overall survival (OS) of patients according to response to 
HDIM 
CR = complete remission, PR = partial remission, SD = stable disease, PD = progressive disease 
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Prognostic indices 
 
The difference in EFS or OS between three prognostic groups defined by the original Josting's 
score (anemia, response duration < 1 year, stage III & IV) was not significant (Table 3) [14]. EFS 
differed significantly between the favourable and unfavorable group but not between either of 
them and the intermediate group as defined by the modified Josting’s score (anemia, response 
duration < 1 y, stage IV) [6]. The difference in OS between these three groups was not significant. 
The index described by Moskowitz and coworkers (B symptoms, response duration < 1 y, stage 
IV) was the only one able to divide patients into three groups with significantly different EFS and 
identify a favorable group with 100% OS [7].  
 
TABLE 3 Prognostic scores  
 
Prognostic score N. of risk 
factors 
% of 
patients 
5-y EFS 
(%) 
p value 
 
Josting's (response 
< 1 year, anemia, 
stage III&IV) [14] 
0 11 86 0 vs. 1        0,198   
1 35 53 0 vs. 2-3     0,092   
2-3 55 52 1 vs. 2-3     0,442   
Modified Josting’s 
(response<1 year, 
anemia, stage IV) 
[6] 
0 15 88 0 vs. 1        0,146 
1 47 56 0 vs. 2-3     0,027 
2-3 38 43 1 vs. 2-3     0,131 
Moskowitz et al 
(response < 1 year, 
stage IV, B) [7] 
0 17 100 0 vs. 1-2     0,026 
1-2 66 56 0 vs. 3         0,002 
3 17 33 1-2 vs. 3      0,015 
 
5-y EFS = 5-year event-free survival 
 
DISCUSSION 
 
This is a retrospective study based on chart-review. In comparison to prospective, controlled 
trials, this type of analysis could lead to underestimation of some types of toxicity and 
overestimation of efficacy. Lack of regular follow-up imaging might result in delayed 
identification of relapses. This should be kept in mind when comparing our results with those of 
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prospective controlled studies.  
The toxicity of HDIM was acceptable, with a specter different from other salvage regimens [3-9]. 
Hematologic and infectious toxicity was very frequent but short. Renal side-effects seem to be 
less severe than with DHAP (due to avoidance of cisplatinum) and duration of pancytopenia 
shorter than with miniBEAM or DexaBEAM. Neurological side-effects occurring in three patients 
were probably related to high-dose ifosfamide. All of them had refractory stage IV HL and severe 
systemic symptoms. HDIM is very emetogenic, intensive antiemetic prophylaxis is needed. The 
toxicity of the regimen is not cumulative; most patients tolerated the second cycle better than the 
first.  
HDIM had excellent mobilization potential. Only two patients who were not progressing on 
treatment failed to collect sufficient stem cells after HDIM but responded to plerixafor. These 
results are probably better than those achieved with miniBEAM or DexaBEAM and similar to 
those of ICE, GDP, IGEV and DHAP.  
Within the limitations imposed by the retrospective nature of the study, the antitumor activity of 
HDIM seems superior to miniBEAM and DexaBEAM and comparable to that of the newer 
regimens (Table 4). A possible exception is IGEV, with a response of 81% and a CR rate of 54% 
[9]. However, EFS after IGEV is similar to that obtained using the other newer regimens, 
suggesting that the observed difference could be a consequence of evaluation at different time-
points (response evaluation of IGEV is performed after 4 and of the other regimens after 2 cycles) 
and not of different antitumor activity. To our knowledge, no phase III trials comparing different 
chemotherapies (e.g. DHAP with ICE or similar) for pretransplant salvage therapy in HL have 
been performed. Therefore, as with large B-cell lymphoma, all of these regimens can still be 
regarded as standard and probably equivalent. The choice between them will depend on need to 
avoid some types of toxicity (i.e. renal for DHAP and neurological for HDIM) and local expertise. 
Irrespective of this, outcome of relapsing or refractory patients receiving very aggressive front-
line therapy such as eBEACOPP will be inferior to that reported.   
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TABLE 4 Results of different regimens used for salvage treatment of HL 
 
Regimen Disease state RR / CR EFS OS 
DexaBEAM [4] relapsed 81% / 27% 45% at 36 mo. NR 
MiniBEAM [3]  all 68% / 32% 36% at 18 mo. 86% at 18 mo. 
 
ICE [7]  
all 88% / 26% 58% at 43 mo. 73% at 43 mo.  
relapsed NR 65% at 43 mo. NR 
refractory NR 52% at 43 mo. NR 
DHAP [5,6]  relapsed 70% / 24% 71% at 36 mo. 87% at 36 mo. 
refractory 65% / 12%  41% at 30 mo. 48% at 30 mo. 
GDP [8]  all 62% / 9% 76% at 18 mo. 90% at 18 mo. 
 
IGEV [9]  
all 81% / 54% 53% at 36 mo.  70% at 36 mo. 
relapsed 85% / 67% NR NR 
refractory 61% / 33% NR NR 
 
HDIM 
all 74% / 32% 56% at 60 mo. 67% at 60 mo. 
relapsed 89% / 41% 69% at 60 mo. 73% at 60 mo. 
refractory 45% / 15% 35% at 60 mo. 55% at 60 mo. 
 
RR = response rate; CR = complete remission rate; EFS = event-free survival; OS = overall 
survival; mo = months;  
 
 
The response to front-line therapy is the most important pretreatment prognostic factor. In all 
studies, including ours, refractory patients fared worse than relapsed. We did not find a difference 
in outcomes between late and early relapsing patients. This is in accordance with some [8, 9, 15], 
but in contrast to other studies [6, 7, 16]. The reason for this is not clear. Multiple studies have 
identified short response duration, extranodal disease, B symptoms and anemia as negative 
prognostic factors. While the influence of any of these alone might not be very important, their 
combination seems to have additive effects. Patients with none have excellent, while those with 
three or more factors have a very poor prognosis. The index described by Moskowitz and 
coworkers was in our series superior to the modified Josting's index [6,7]. The original Josting's 
score, with disease stages III and IV considered unfavorable, was not of prognostic significance 
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[12]. A similar finding was reported previously in studies using dose-dense therapy with ICE and 
DHAP [6,7]. This suggests that short dose-dense treatment improves outcomes of nodal more 
than extranodal relapsed and refractory HL.  
As in all other studies that analyzed it, response to salvage treatment was the most important 
prognostic factor. The outcome of patients with refractory disease who responded to HDIM was 
rather good, and more than half were cured with autografting (and radiotherapy in selected cases). 
Our experience indicates that patients with stable disease after salvage chemotherapy should not 
go on to ASCT. Only 2 of them did not relapse, both have received posttransplant radiotherapy. 
Recent studies suggest that PET-CT response evaluation prior to ASCT has an even better 
prognostic value and should be used to determine whether patients should proceed to transplant 
and/or receive posttransplant brentuximab consolidation [17,18].  
Median OS in patients with SD after HDIM was longer than 3 years. This indicates that, even 
before the availability of brentuximab-vedotin, non cross-resistant chemotherapy treatment 
options existed for relapsed and refractory HL, and only patients progressing during treatment had 
a dismal prognosis. Some of those responding to subsequent lines of treatment can be cured with 
ASCT and radiotherapy. This is in accordance with the guidelines of the French Lymphoma 
Study Association [2] and results of Gerrie and coworkers [19], and in contrast to those of Villa 
and coworkers [20]. The outcome of this high-risk patient population can possibly additionally be 
improved with the use of double-transplants or combinations of brentuximab with chemotherapy 
[21,22].   
In conclusion, HDIM is an effective treatment for relapsed and refractory HL with acceptable 
toxicity and excellent mobilizing potential. It should be added to the armamentarium of salvage 
regimens for this type of lymphoma.  
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